- Companies
- Verge Genomics
Verge Genomics Funding, Investors & Competitors
Verge Genomics has raised $134M across 4 funding rounds, most recently a $98M Series B in December 2021.
Last Verge Genomics funding round
$98M
Series B · Dec 2021
Cumulative funding Verge Genomics raised
$134M
across 4 funding rounds
Key investors in Verge Genomics
Threshold
Lifeforce Capital
Y Combinator
Alumni Ventures
Slow Ventures
Great Oaks Venture Capital
Draper Associates
BlackRock
About Verge Genomics
Verge Genomics is a South San Francisco-based biotechnology company applying machine learning to neurodegenerative drug discovery. Founded in 2012, it analyzes genomic datasets from over 100,000 patients to identify targets for ALS, Parkinson's, and Alzheimer's. Verge Genomics has advanced VRG50635 into Phase 2 trials for ALS and partnered with Barrow Neurological Institute, raising $67 million from investors including Khosla Ventures and Alexa Ventures.
Founded
2015
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Product sales, Subscription
Verge Genomics Funding History
Verge Genomics has raised a total of $134M across 4 funding rounds.
Verge Genomics' first fundraising round was a $100K pre-seed round in June 2015. The most recent completed round was a $98M Series B in December 2021.
Verge Genomics funding rounds
| Date | Stage | Investors | Raised | Deal Summary |
|---|---|---|---|---|
| Dec 2021 | Series B | BlackRock (lead); Tao Capital Partners; S32; Merck Global Health Innovation Fund; Alumni Ventures; Vulcan Capital; Eli Lilly; ALS Investment Fund; Lifeforce Capital; Threshold | $98M | Verge Genomics, a clinical-stage biotechnology company founded in 2015, uses artificial intelligence combined with human genomics to identify drug targets and develop therapeutics for neurodegenerative diseases. The company developed a proprietary platform called CONVERGE® that leverages AI and comprehensive human genomic and multi-omic patient data to accelerate drug discovery, with particular focus on amyotrophic lateral sclerosis (ALS) and Parkinson's disease. The company maintains one of the largest genomic databases of human patients with neurodegenerative diseases in the field. In July 2021, Verge Genomics signed a three-year partnership with Eli Lilly to identify and validate new ALS drug targets, with Eli Lilly paying $25 million upfront and having the option to advance up to four candidates into clinical development, with potential milestone payments of up to $694 million if drugs reach the market. Verge Genomics closed its Series B financing round on December 16, 2021, raising $98 million in equity funding. The oversubscribed round was led by funds managed by BlackRock and included new investors Eli Lilly, Merck Global Health Innovation Fund, Section 32, and Vulcan Capital, alongside existing investors including Threshold Ventures, ALS Investment Fund, Tao Capital Partners, and Lifeforce Capital. The new capital will accelerate preclinical and clinical programs in the company's pipeline, advance lead programs through clinical development, and enhance the CONVERGE® platform's computational capabilities. As a clinical-stage biotech company at the time, Verge Genomics had not yet generated material revenue or reported EBITDA metrics. |
| Jul 2018 | Series A | Threshold (lead) | $32M | Verge Genomics, a San Francisco-based drug discovery company founded in 2015, utilizes machine learning, neuroscience, and experimental biology to accelerate development of therapeutics for neurodegenerative diseases like ALS and Parkinson’s. The company announced an oversubscribed $32 million Series A financing on July 16, 2018, led by DFJ, with participation from WuXi AppTec’s Corporate Venture Fund, ALS Investment Fund, Agent Capital, and OS Fund. This round brought total funding to over $36 million. Threshold is listed as an existing investor in later rounds but not as lead or participant in this Series A. Proceeds from the Series A were intended to advance promising drug candidates toward clinical trials, expand proprietary datasets including one of the largest databases of ALS and Parkinson’s patient genomic data from partnerships with academic and government organizations, and grow the therapeutic portfolio. The company had already identified dozens of therapeutic opportunities and established partnerships with two pharmaceutical companies. Emily Melton of DFJ joined the board following the financing. Later financings include a $98 million Series B in December 2021 led by BlackRock with Eli Lilly, Merck GHI, and others, and subsequent rounds up to a Series C at $403.75MM valuation in September 2023, with total funding exceeding $167 million. |
| Oct 2015 | Seed | IA Ventures (lead); Kimberly Vogel; Slow Ventures; Refactor; Great Oaks Venture Capital; Lifeforce Capital; OS Fund; Karlin Ventures; Draper Associates; Two Sigma Ventures | $4M | Verge Genomics closed a $4 million seed financing round on approximately October 29, 2015, led by IA Ventures with participation from Draper Associates, Great Oaks Venture Capital, Karlin Ventures, Kimberly Vogel, Lifeforce Capital, OS Fund, Refactor, Slow Ventures, and Two Sigma Ventures. The company, founded in 2015, develops therapeutics using machine learning, neuroscience, and experimental biology, focusing on ALS and Parkinson’s disease. Verge Genomics built proprietary datasets of patient genomic data through partnerships with academic and government organizations. |
| Jun 2015 | Pre-seed | Y Combinator (lead) | $100K | - |
Who has invested in Verge Genomics?
20 investors have backed Verge Genomics across its funding rounds, including Threshold, Lifeforce Capital, Y Combinator, Alumni Ventures, Slow Ventures and Great Oaks Venture Capital.
Lead investors include BlackRock, Threshold, IA Ventures and Y Combinator.
Verge Genomics Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 2 | Participant | Oct 2015 | ||
| 2 | Lead | Jul 2018 | ||
| 1 | Participant | Dec 2021 | ||
| 1 | Participant | Oct 2015 | ||
| 1 | Lead | Jun 2015 | ||
| 1 | Participant | Oct 2015 | ||
| 1 | Participant | Dec 2021 | ||
| 1 | Participant | Oct 2015 | ||
| 1 | Lead | Oct 2015 | ||
| 1 | Participant | Dec 2021 | ||
| 1 | Participant | Dec 2021 | ||
| 1 | Participant | Dec 2021 | ||
| 1 | Lead | Dec 2021 | ||
This data is available for Pro users. Sign up to see all 20 Verge Genomics investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialVerge Genomics Competitors
Verge Genomics competitors include listed companies like SAP and Snowflake, and private ones like Astromech, Chai Discovery, Anthropic and OpenAI.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Private | - | - | $3.8B | - | ||
| Private | $48M | - | $3.8B | - | ||
| Private | $47B | - | $965B | 20.5x | ||
| Private | $25B | - | $852B | 34.1x | ||
| Publicly listed | $42B | $13B | $248B | 5.4x | ||
| Publicly listed | $4.7B | ($1.3B) | $119B | 21.0x |
Verge Genomics Public Comps
Verge Genomics is still privately-owned, but its public comps include Eli Lilly, Johnson & Johnson, AbbVie, Merck, Roche, Novartis, AstraZeneca, CrowdStrike, SAP and Amgen.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $65B | $28B | 16.5x | 13.1x | 38.7x | 27.0x | |||
| $94B | $40B | 7.2x | 6.8x | 17.0x | 18.3x | |||
| $61B | $17B | 8.7x | 8.1x | 30.6x | 17.6x | |||
| $65B | $28B | 6.3x | 6.2x | 14.7x | 21.0x | |||
| $77B | $26B | 5.0x | 4.9x | 14.6x | 12.4x | |||
| $57B | $22B | 5.5x | 5.5x | 14.2x | 13.3x | |||
| $59B | $19B | 4.8x | 4.5x | 14.6x | 12.7x | |||
| $4.8B | ($12M) | 51.4x | 44.5x | (19816.2x) | 151.0x | |||
This data is available for Pro users. Sign up to see all Verge Genomics competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Verge Genomics
| When was Verge Genomics founded? | Verge Genomics was founded in 2015. |
| Where is Verge Genomics headquartered? | Verge Genomics is headquartered in San Francisco, CA, United States. |
| Is Verge Genomics publicly listed? | No, Verge Genomics is a private, VC-backed company. |
| How much funding has Verge Genomics raised? | Verge Genomics has raised $134M across 4 funding rounds. |
| What was Verge Genomics' last funding round? | Verge Genomics' last funding round was a $98M Series B in December 2021, led by BlackRock. |
| Who are Verge Genomics' investors? | Verge Genomics' investors include Lifeforce Capital, Threshold, Tao Capital Partners, Kimberly Vogel, Y Combinator, Slow Ventures, S32, Refactor, IA Ventures, Merck Global Health Innovation Fund and 10 others. |
| Which companies are comparable to Verge Genomics? | Companies comparable to Verge Genomics include Astromech, Chai Discovery, Anthropic, OpenAI, SAP and Snowflake. |
See companies similar to Verge Genomics
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




